Stocktoria
HeartSciences Inc. HSCS
HeartSciences Inc. (HSCS) earns a Piotroski F-score of 1/9 (weak financial health). It does not currently pay a dividend. FY2025 revenue was $4,350 at a -201499.5% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 1/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| HSCS | HeartSciences Inc. | 1/9 | — | — | — |
| CUPR | Cuprina Holdings (Cayman) LTD | 4/9 | -2.57 | — | — |
| COCH | Envoy Medical, Inc. | 2/9 | — | — | — |
| SPAI | Safe Pro Group Inc. | 4/9 | 9.05 | — | — |
| AVR | Anteris Technologies Global Corp. | 2/9 | — | — | — |
| NTRB | NutriBand Inc. | 3/9 | -15.84 | — | — |
| CLGN | CollPlant Biotechnologies Ltd | 3/9 | — | — | — |
About HeartSciences Inc.
HeartSciences Inc., a medical technology company, focuses on applying AI-based technology to an ECG to expand and improve clinical usefulness. It develops artificial intelligence-enhanced electrocardiography (AI-ECG) solutions, an algorithm to detect impaired cardiac relaxation or cardiac dysfunction caused by heart disease and/or age-related cardiac dysfunction; MyoVista wavECG device, a resting 12-lead ECG that provides diagnostic information related to cardiac dysfunction, as well as conventional ECG information in the same test; and MyoVista Insights, a cloud-based platform to host AI-ECG algorithms on an ECG hardware agnostic basis. The company was formerly known as Heart Test Laboratories, Inc. and changed its name to HeartSciences Inc. in October 2024. HeartSciences Inc. was incorporated in 2007 and is headquartered in Southlake, Texas.
FAQ
Is HSCS financially healthy?
HeartSciences Inc.'s Piotroski F-score is 1/9 (8–9 is excellent, 0–3 weak).
Does HSCS pay a dividend?
No, HeartSciences Inc. does not currently pay a dividend.
How profitable is HSCS?
In FY2025, HeartSciences Inc. had a net margin of -201499.5% and a return on equity of -4272.2%.
What is the analyst price target for HSCS?
The average Wall-Street price target for HeartSciences Inc. is $10.00, about 400.0% above the recent price, from 2 analysts.
Is HSCS a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on HeartSciences Inc.: a Piotroski F-score of 1/9. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-04-30. Facts plus Stocktoria's own computed scores — not investment advice.